← 返回

NK3 亚群与肿瘤中 NK 细胞耗竭及免疫治疗应答相关

英文原题:NK3 subsets are linked to NK cell exhaustion and immunotherapy responsiveness in tumor.

查看英文原题

NK3 subsets are linked to NK cell exhaustion and immunotherapy responsiveness in tumor.

PubMed 2026/09/11(内容时间) Semin Oncol Q1 · IF 6.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤(NK)细胞构成人体免疫防御的第一道防线。由于其强大的细胞毒性、强效的细胞因子分泌和免疫调节能力,NK细胞在肿瘤免疫领域引起了广泛研究。然而,慢性肿瘤抗原暴露会诱导NK细胞耗竭(NK-ex)。本研究利用NK细胞的公共单细胞RNA测序数据集,鉴定NK-ex亚群,并通过计算轨迹排序绘制转录连续谱。我们的研究揭示,在肿瘤患者中,NK3相比其他NK亚群表现出更多耗竭特征。淋巴细胞活化基因3(LAG-3)表达在NK-ex亚群中相对特异性富集。临床分析推断,功能上占主导的NK-ex亚群与免疫检查点阻断(ICB)治疗的应答强烈相关,且治疗后可观察到向耗竭方向的表型转变。本研究初步刻画了NK-ex亚群,并提示LAG-3可能参与调控NK细胞耗竭的进展,这可能为开发靶向NK-ex细胞的免疫治疗策略提供潜在的理论参考。

展开英文摘要原文

Natural killer (NK) cells constitute the first line of human immune defense. They have attracted extensive research in the field of tumor immunity owing to their potent cytotoxicity, robust cytokine secretion, and immunomodulatory capacity.

However, chronic tumor antigen exposure would induce exhaustion in NK cells (NK-ex).

This study leverages public single-cell RNA sequencing datasets of NK cells to identify NK-ex subsets and map a transcriptional continuum derived from computational trajectory ordering.

Our investigation revealed that NK3 exhibited more exhaustion features compared to other NK subsets in tumor patients. lymphocyte-activation gene 3 (LAG-3) expression is relatively specific enriched in the NK-ex subpopulation. Clinical analyses infer that functionally dominant NK-ex subsets are strongly correlated with responses to immune checkpoint blockade (ICB) therapy, and phenotypic shifts toward exhaustion can be observed post-treatment.

This study preliminarily characterizes NK-ex subpopulations and suggests that LAG-3 may participate in regulating the progression of NK cell exhaustion, which could offer potential theoretical references for developing immunotherapeutic strategies targeting NK-ex cells.

论文信息

作者
Gou ZX、Bao YT、Liu LH、Xie J、Ding YY、Huang XJ、Zhao XY
第一作者单位
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.China
通讯作者单位
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China. Electronic address: zhao_xy@bjmu.edu.cn.China
期刊
Seminars in oncology2026 Sep 11
原文标识
PubMed 42762807 · DOI 10.1016/j.seminoncol.2026.152562